- Home
- APGE
as 11-15-2024 4:00pm EST
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 3.0B | IPO Year: | 2023 |
| Target Price: | $75.20 | AVG Volume (30 days): | 366.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.39 - $72.29 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Apogee Therapeutics Inc. (APGE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dambkowski Carl | APGE | Chief Medical Officer | Oct 2 '24 | Sell | $56.51 | 6,665 | $374,953.90 | 275,053 | |
| HENDERSON MICHAEL THOMAS | APGE | Chief Executive Officer | Oct 2 '24 | Sell | $56.41 | 40,000 | $2,249,307.04 | 1,354,487 | |
| Dambkowski Carl | APGE | Chief Medical Officer | Sep 4 '24 | Sell | $47.78 | 6,665 | $316,969.44 | 275,053 | |
| HENDERSON MICHAEL THOMAS | APGE | Chief Executive Officer | Sep 4 '24 | Sell | $47.75 | 40,000 | $1,904,841.05 | 1,354,487 | |
| Henderson Jane | APGE | Chief Financial Officer | Aug 23 '24 | Sell | $48.26 | 6,000 | $289,560.00 | 200,871 |
Latest Apogee Therapeutics Inc. News
APGE Breaking Stock News: Dive into APGE Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans
TipRanks
4 days ago
Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028
MT Newswires
5 days ago
Apogee Therapeutics' Q3 Net Loss Widens
GlobeNewswire
5 days ago
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
GlobeNewswire
13 days ago
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
GlobeNewswire
24 days ago
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
GlobeNewswire
a month ago
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
Insider Monkey
a month ago
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now
Compare APGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APGE Apogee Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.